Compass Pathways' depression treatment meets main goal in late‑stage study

Compass Pathways' depression treatment meets main goal in latestage study | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]- Companies[Compass Pathways PLC]FollowFeb 17 (Reuters) - Drug developer Compass Pathways [(CMPS.O), opens new tab] said on Tuesday its psilocybin-based depression therapy met the main goal in a late-stage study.Sign up [here.]Reporting by Sahil Pandey in Bengaluru; Editing by Devika SyamnathOur Standards: [The ...